Yan A, Bryant E. Quinolones. StatPearls. Treasure Island: StatPearls Publishing; 2022.
Adriaenssens N, Bruyndonckx R, Versporten A, Hens N, Monnet DL, Molenberghs G, et al. Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997–2017. J Antimicrob Chemother. 2021;76:30–6.
Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44:161–4.
Article PubMed PubMed Central Google Scholar
Hopper D, Jacoby G. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;176:139–48.
European Centre for Disease Prevention and Control (ECDC). Antimicrobial Resistance in the EU/EEA—a One Health response. 2022. https://www.ecdc.europa.eu/sites/default/files/documents/antimicrobial-resistance-policy-brief-2022.pdf Accessed 4 Nov 2022.
Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin Ther. 2016;38:1930–47.
Article CAS PubMed PubMed Central Google Scholar
Pino-Marín DE, Madrigal-Cadavid J, Amariles P. Clinical relevance of drug interactions with antibiotics related to changes in the absorption: structured review. Ces Med. 2018;32:235–49.
Gregg CR. Drug interactions and anti-infective therapies. Am J Med. 1999;106:227–37.
Article CAS PubMed Google Scholar
Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet. 1990;18:210–9.
Article CAS PubMed Google Scholar
Sulochana SP, Syed M, Chandrasekar DV, Mullangi R, Srinivas NR. Clinical drug–drug pharmacokinetic interaction potential of sucralfate with other drugs: review and perspectives. Eur J Drug Metab Pharmacokinet. 2016;41:469–503.
Article CAS PubMed Google Scholar
Pai MP, Allen SE, Amsden GW. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. J Cyst Fibros. 2006;5:153–7.
Article CAS PubMed Google Scholar
Mallet L, Huang A. Coadministration of gatifloxacin and multivitamin preparation containing minerals: potential treatment failure in an elderly patient. Ann Pharmacother. 2005;39:150–2.
Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. Antimicrob Agents Chemother. 2020;64:e02167-e2219.
Article CAS PubMed PubMed Central Google Scholar
Wiesner A, Zagrodzki P, Paśko P. Do dietary interventions exert clinically important effects on the bioavailability of beta-lactam antibiotics? A systematic review with meta-analyses. J Antimicrob Chemother. 2024;79:722–57.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1–8.
Higgins JPT, Li T, Sterne JAC. Revised Cochrane risk of bias tool for randomized trials (RoB 20): Additional considerations for crossover trials. Cochrane Methods. 2021;1–6.
NIH. Study quality assessment tools. 2022. https://www.nhlbi.nih.gov/health‐topics/study‐quality‐assessment‐tools Accessed 25 Jun 2022.
Higgins JPT, White IR, Anzures-Cabrera J. Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales. Stat Med. 2008;27:6072–92.
Article PubMed PubMed Central Google Scholar
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
Article PubMed PubMed Central Google Scholar
Deeks J, Higgins J, Altman D. Chapter 10: Analysing data and undertaking meta-analyses. In: Cochrane Handb Syst Rev Interv version 63. 2022.
Ohnishi A, Toyoki T, Yoshikawa K, Hashizume K, Tanigawa T, Tanaka T, et al. Safety, pharmacokinetics and influence on the intestinal flora of BAY 12–8039 (moxifloxacin hydrochloride) after oral administration in healthy male subjects. Jpn Pharmacol Ther. 2005;33:1029–45.
Zhang J, Zhang Y-Y, Shi Y-G, Yu J-C, Wang L. Clinical pharmacokinetic study on ciprofloxacin. Chin Pharmacol Bull. 1996;12:430–3.
FDA. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf Accessed 1 Jul 2022.
Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm Drug Res. 2009;66:587–604.
Culley CM, Lacy MK, Klutman N, Edwards B. Moxifloxacin: clinical efficacy and safety. Am J Heal Pharm. 2001;58:379–88.
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32:101–19.
Article CAS PubMed Google Scholar
Blokhina SV, Sharapova AV, Ol’khovich MV, Volkova TV, Perlovich GL. Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials. Eur J Pharm Sci. 2016;93:29–37.
Article CAS PubMed Google Scholar
Wiesner A, Skrońska M, Gawlik G, Marcinkowska M, Zagrodzki P, Paśko P. Interactions of antiretroviral drugs with food, beverages, dietary supplements, and alcohol—a systematic review and meta-analysis. AIDS Behav. 2023;27:1441–68.
Wiesner A, Gajewska D, Paśko P. Levothyroxine interactions with food and dietary supplements—a systematic review. Pharmaceuticals. 2021;14:206.
Article CAS PubMed PubMed Central Google Scholar
Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. Lancet. 1986;2:294.
Article CAS PubMed Google Scholar
Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrobal Agents Chemother. 1991;35:1004–7.
Lomaestro BM, Bailie GR. Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother. 1993;27:1325–8.
Article CAS PubMed Google Scholar
Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992;36:830–2.
Article CAS PubMed PubMed Central Google Scholar
Walden DM, Khotimchenko M, Hou H, Chakravarty K, Varshney J. Effects of magnesium, calcium, and aluminum chelation on fluoroquinolone absorption rate and bioavailability: a computational study. Pharmaceutics. 2021;13:594.
Article CAS PubMed PubMed Central Google Scholar
Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW. Lack of bioequivalence 4f ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42:461–6.
Sultana R, Ullah A, Akbor MM, Azad MAK, Latif AHMM, Hasnat A. Effect of orange juice on bioavailability of levofloxacin. J Appl Res. 2008;8:34–42.
Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol. 2003;43:539–44.
Park MS, Okochi H, Benet LZ. Is ciprofloxacin a substrate of P-glycoprotein? Arch Drug Inf. 2011;4:1–9.
Article CAS PubMed PubMed Central Google Scholar
Cravens MG, Sherman N, Sawaya J. Ciprofloxacin-induced Stevens–Johnson syndrome with grapefruit juice consumption: a case report. Cureus. 2019;11: e3827.
PubMed PubMed Central Google Scholar
Matsumoto F, Sakurai I, Imai T, Ishida Y, Takahashi T, Morita M, et al. Fundamental and clinical studies on pazufloxacin. Jpn J Chemother. 1995;43:244–56.
Staib AH, Stille W, Dietlein G, Shah PM, Harder S, Mieke S, et al. Interaction between quinolones and caffeine. Drugs. 1987;34:170–4.
Article CAS PubMed Google Scholar
Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1989;33:474–8.
Article CAS PubMed PubMed Central Google Scholar
Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther. 1989;45:234–40.
Article CAS PubMed Google Scholar
Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of interaction between lomefloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1991;35:660–4.
留言 (0)